Cystinuria Clinical Trial
Official title:
Phase 2 Multi-Center, Dose Escalation Trial To Assess The Safety And Effectiveness Of Bucillamine On Urinary Cystine Excretion And Cystine Capacity In Patients With Cystinuria
Subjects on a standard regimen of tiopronin (cystine binding thiol drug; CBTD) plus
prescribed first-line therapy (i.e. on a hydration, alkali therapy and dietary restriction)
who are failing therapy will be selected for this trial.
After completing informed consent, the subject will have Screening consisting of medication
history and physical examination with vital signs. Samples of blood and urine will be taken
for clinical laboratory and urinalysis. Patients will undergo a 12-lead ECG test. A history
of side effects with current CBTD as well as laboratory recordings of abnormalities
attributable to treatment will also be recorded.
Subjects will be dosed in a sequential manner, starting with the low dose group (300
mg/day), then proceeding to the 600 mg.day dose group.. Safety and tolerability will be
monitored closely by an Independent Medical Monitor (IMM) and based on the IMM's assessment
that it is safe to proceed to the higher dose (600 mg/day), subsequent subjects will be
enrolled into that group. Up to 15 subjects each will be enrolled into either Group A or
Group B.
After 7 days on the assigned bucillamine dose, a 24-hour urine sample will be taken and
after completing the Day 8 safety visit, subjects will undergo a 7 day washout where no
CBTDs will be taken. Thereafter, subjects will be allowed to resume their originally
prescribed CBTDs under Investigator's supervision.
One week following study drug discontinuation, subjects will return to the clinic for
follow-up safety assessments.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | March 2018 |
Est. primary completion date | March 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: 1. Subjects of any gender and of any race =18 and =80 years of age 2. Subjects with proven cystinuria who are failing their standard drug therapy of tiopronin plus first-line therapy (hydration, alkali and diet restriction) and who meet the following criteria. - formed new stones while taking a thiol. - had increase in stone size of pre-existing stones while taking a thiol. - had a urologic intervention for stones while taking a thiol 3. Subjects must be able to reliably urinate in a collection vessel and measure urine volume 4. Subjects must have documentation of a stable complete blood count (CBC) and urinalysis (UA) in the 6 months prior to date of enrollment 5. Subjects may have a history of but not currently active CNS disorders or symptoms/effects (e.g., headache) 6. Subjects must have adequate organ function, evidenced by the following laboratory results within 30 days prior to enrollment: - Absolute neutrophil count >2000 cells/mm - Platelet count >140,000 cells/mm3 - Hemoglobin >11.0 g/dl - Albumin =2.5 g/dl - Total bilirubin =1.5 upper limit of normal (ULN) - SGOT (aspartate aminotransferase [AST]), SGPT (alanine aminotransferase [ALT]), and alkaline phosphatase (ALP) = 2.5 x ULN - eGFR >60 ml/min/173m 2 based on Modification of Diet and Renal Disease (MDRD) Study equation which includes the variables of creatinine, age, sex and race 7. Female subject who has been post-menopausal for at least 24 consecutive months, or women who have undergone surgical sterilization, (e.g. hysterectomy, bilateral oophorectomy, tubal ligation or salpingectomy) is eligible without requiring the use of a contraceptive methods described in Inclusion #8 8. For women of childbearing potential and men with partners of childbearing potential, agreement to use a highly effective, non-hormonal form of contraception: - Acceptable forms of should include two of the following: - Placement of intrauterine device (IUD) or intrauterine system (IUS) - Condom with spermicidal foam/gel/film/cream/suppository - Diaphragm or cervical/vault caps with spermicidal foam/gel/film/cream/suppository - The above contraception is not a requirement in the case of any of the following: - Subject is surgically sterilized - Subject has had no menstrual period for 12 consecutive months - Contraception use should continue for the duration of the study treatment and for at least 3 months after the last dose of study treatment Periodic abstinence (e.g., calendar ovulation, symptom-thermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception 9. Subjects must be willing and able to give written informed consent Exclusion Criteria: 1. Subjects with renal colic 2. Subjects who are scheduled to undergo a surgical procedure 3. Subjects on D-penicillamine (see page 35 for explanation) 4. Subjects with cancer 5. Subjects with acute or chronic infections including HIV, tuberculosis, hepatitis B or hepatitis C 6. Patients with proteinuria =30 mg that is confirmed on repeat laboratory assessment within 24 hours 7. Subjects with QTc interval >450 ms 8. A history of, hypokalemia and family history of Long QT syndrome 9. Use of concomitant medications that may prolong QT/QTc interval 10. Patients with significant heart failure and activity impairment (Class III-IV of the New York Heart Association (NYHA) 11. Subjects with serious hepatic disorder (Child-Pugh scores B or C) 12. Subjects with a history of alcohol or substance abuse within the 12 months prior to enrollment 13. Subjects with history of or active blood dyscrasia such as myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, and aplastic anemia. 14. Subjects with Coagulopathy (regardless if controlled by pharmacotherapy or not) 15. Subjects who have any concomitant illness (including active significant infection) or other finding that, in the opinion of the Investigator, would confound the study data or place the subject at unacceptable risk if the subject were to participate in the study, or that would require frequent adjustments in concomitant medications during the course of the study 16. Use of any investigational drug within 30 days prior to enrollment 17. Subjects currently participating in another research study or anticipated to enroll in such during participation in this study 18. Subjects for whom informed consent cannot be obtained |
Country | Name | City | State |
---|---|---|---|
United States | University of Alabama - Department of Urology | Birmingham | Alabama |
United States | Massachusette General Hospital | Boston | Massachusetts |
United States | University of Wisconsin School of Medicane and Public Health | Madison | Wisconsin |
United States | New York University School of Medicine | New York | New York |
United States | Omega Medical Research | Warwick | Rhode Island |
Lead Sponsor | Collaborator |
---|---|
Revive Therapeutics, Ltd. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] | Number, type, and severity of AEs observed by the staff during visits on Days 0 (dosing), 3, 8 and +1 week post-study or volunteered by the subject during telephone follow-up on Days 2 and 7. | Days 0, 2, 3, 7, 8 and + 1 wk post study | |
Secondary | Cystine Excretion | Measurement of 24-hr urine cystine excretion. | Day 0 and Day 8 | |
Secondary | Cystine Capacity | Measurement of 24-hr urine cystine capacity, i.e., the capacity of a patient's urine to solubilize or precipitate. | Day 0 and Day 8 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02120105 -
Cystine Capacity Clinical Study (CysCap)
|
||
Completed |
NCT02538016 -
TCUPS- Tolvaptan Use in Cystinuria and Urolithiasis: A Pilot Study
|
N/A | |
Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
Recruiting |
NCT00169806 -
Randall's Plaque Study: Pathogenesis and Relationship to Nephrolithiasis
|
N/A | |
Completed |
NCT03663855 -
Effect of Increasing Doses of Tiopronin on Cystine Capacity in Patients With Cystinuria
|
Phase 2 | |
Recruiting |
NCT02780297 -
Prospective Research Rare Kidney Stones (ProRKS)
|
||
Recruiting |
NCT02026388 -
Rare Kidney Stone Consortium Biobank
|
||
Recruiting |
NCT04818034 -
The Effect of Sodium-glucose Cotransporter (SGLT) 2 Inhibitors on Cystine Stone Formation: A Preliminary Study
|
Phase 2 | |
Withdrawn |
NCT04137978 -
Study Evaluating Patients With Cystinuria
|
Phase 2/Phase 3 | |
Completed |
NCT05048563 -
Registry of Thiola EC Therapy
|
||
Not yet recruiting |
NCT04147871 -
Study Evaluating Patients With Cystinuria and Efficacy and Safety Exploratory Study in the Youngest Children
|
Phase 2/Phase 3 | |
Completed |
NCT02125721 -
Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria
|
Phase 4 | |
Active, not recruiting |
NCT02910531 -
Lipoic Acid Supplement for Cystine Stone
|
Phase 2 | |
Recruiting |
NCT00588562 -
Rare Kidney Stone Consortium Patient Registry
|
||
Completed |
NCT02124395 -
Health-related Quality of Life in Rare Kidney Stone
|
||
Not yet recruiting |
NCT05058859 -
Long Term Clinical Efficacy of Sodium-glucose Cotransporter-2 (SGLT-2) Inhibitor in Cystinurics
|
Phase 2 | |
Active, not recruiting |
NCT03539926 -
This Study Evaluates the Superiority of Daily Self-pH Monitorization of Lit-control®pH Meter Compared to the Monitorization of Reactive Strips (Standard of Care).
|
N/A | |
Completed |
NCT00381849 -
Use of an Herbal Preparation to Prevent and Dissolve Kidney Stones
|
Phase 1/Phase 2 | |
Completed |
NCT03836144 -
Effect of Urine Alkalinazation on Urinary Inflammatory Markers in Patients With Cystinuria
|